Navigation Links
ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
Date:3/3/2009

mation for ExonHit: a new organization was put in place and a thorough business review was conducted. We want to stay active in both Therapeutics and Diagnostics and increase our collaborations," said Dr. Loic Maurel, President of the Management Board of ExonHit Therapeutics. "In Therapeutics, our strategy is to out-license our products or programs to maximize returns on investment. In Diagnostics, we plan to take products to the market and are currently evaluating opportunities to strengthen our overall portfolio and capabilities."

In July 2008, a new Management Board was elected following the departure of Bruno Tocque, Fabien Schweighoffer and Laurent Bracco, ExonHit's co-founders. All three retain a consultancy role in the collaboration with Allergan. Loic Maurel was named President of the Management Board, Matt Pando, Head of the Therapeutics Division and John Jaskowiak, Head of the Molecular Diagnostic & Genomic Services Division. Philippe Rousseau remains on the Management Board as Chief Financial Officer.

Overview of ExonHit's business activities

In order to transform into an emerging healthcare player, ExonHit Therapeutics underwent significant changes in 2008. For the first time, the Company simultaneously invested in clinical testing in both diagnostics and therapeutics. In addition, further investment was made to prepare its internal service laboratories to be compliant with Good Laboratory Practices (GLP).

ExonHit Therapeutics will keep its diversified business model and remain active in both therapeutics and diagnostics. These two fields have distinct risks and returns on investment, and provide opportunities for synergistic value creation. ExonHit will pursue its balanced investment strategy, with internal development programs and an increased number of strategic collaborations. Genomic Services activities are now dedicated to generating new collaborations for both the
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI)
2. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
3. Loic Maurel Joins Exonhit Therapeutics to Become CEO
4. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
5. Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
6. ExonHit Appoints a New Management Board
7. ExonHit Therapeutics - 2007 Financial Results
8. ExonHit Builds A New Organisation
9. ExonHit and bioMerieux Amend Their Strategic Partnership
10. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
11. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Riordan-McKenna Institute ... announced today that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed by ... otherwise non-healing surgical knee wound. , The case involved a 78-year-old male, who ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... venture capital funds, investment firms and animal health companies to hear from animal ... $160 million. Several have also received licensing agreements or distribution contracts. This ...
(Date:8/27/2015)... 27, 2015  Neogen Corporation (NASDAQ: NEOG ) ... United Kingdom -based Lab M Holdings, ... and diagnostic systems. Lab M was ... provider of microbial testing and diagnostic products for the ... company currently sells into more than 70 countries worldwide, ...
(Date:8/27/2015)... -- The National Necrotizing Fasciitis Foundation (NNFF) ... doctors at Vanderbilt University Hospital in Nashville, ... Dr. John Crew , director of the ... in Daly City, CA. ... by Dr. Crew, that had previously saved the lives ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3
... SAN DIEGO, Oct. 16 CardioDynamics (Nasdaq:,CDIC), ... technology,has been named to Deloitte,s prestigious Technology Fast ... 50 fastest growing technology, media,telecommunications, and life sciences ... LLP, one of the nation,s leading professional services,organizations. ...
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... presentations at the AACR-NCI-EORTC,International Conference on Molecular Targets ... They will highlight drug discovery,efforts focused on significant ... like kinase 1 (PLK1) and Janus tyrosine kinase,2 ...
... Stockholder Meeting October 23, IRVINE, California, October ... an orthobiologics company, today announced the,interim tabulation results ... 2007 and adjourned to October 23, 2007. ... 36 percent,of the shares entitled to vote, voted ...
Cached Biology Technology:CardioDynamics Ranked in Deloitte's Technology Fast 50 Program for San Diego 2CardioDynamics Ranked in Deloitte's Technology Fast 50 Program for San Diego 3CardioDynamics Ranked in Deloitte's Technology Fast 50 Program for San Diego 4Rigel to Present Research Programs at Scientific Conferences 2Rigel to Present Research Programs at Scientific Conferences 3IsoTis Reports Interim Results of Vote for Integra Merger 2IsoTis Reports Interim Results of Vote for Integra Merger 3IsoTis Reports Interim Results of Vote for Integra Merger 4
(Date:8/4/2015)... ) today reported financial and operating results for the second quarter ... quarter contract revenue of $ 85.2 million, a ... of 26 % , Second quarter adjusted ... royalties in the current quarter , Operating cash ... to present another strong financial quarter, with all our divisions achieving ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
(Date:7/31/2015)... de julio de 2015 La 10 th ... por medio de BGI del 22 al 25 de octubre de ... Este año, la conferencia celebra su décimo aniversario. Desde ... en una de las reuniones anuales más influyentes del mundo ... reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... A Duke University study suggests that evolution can behave ... depend on an energy-efficient style of four-footed running over ... have evolved a profoundly inefficient gait, tailor-made to creep ... "It is usually assumed that efficiency is what ...
... Using a harmless virus to insert a corrective gene ... Research Hospital have alleviated sickle cell disease pathology. In ... showed essentially no difference from normal mice. Although the ... presents significant technical obstacles, they believe that the new ...
... failing to take their medication for a range of ... a new university research project. The 21-month study ... The University of Leicester will draw on the experiences ... and epilepsy to learn about the barriers that prevent ...
Cached Biology News:Dogs chase efficiently, but cats skulk counterintuitively 2Gene therapy corrects sickle cell disease in laboratory study 2Gene therapy corrects sickle cell disease in laboratory study 3A spoonful of sugar? 2A spoonful of sugar? 3
... The OneSTrEP Protein Interaction Kit provides ... step method to isolate intact protein ... tedious optimization or multiple purification steps, ... highly selective StrepTactin Superflow Column for ...
Request Info...
... The system consists ... (Cat. No. 17001-082) and ... 17002-080). It is complete ... promoting agents, and requires ...
... The product contains 5 ml Dynabeads Tosylactivated ... p-toluenesulphonyl (tosyl) reactive groups. For coupling of ... hydrophobically on initial coupling with covalent binding ... and sulphydryll groups (SH)) occurringovernight. Coupling reactions ...
Biology Products: